Actinium Pharmaceuticals, Inc. (ATNM)

Revenue growth of 3986.96% while RVPH is flat. Bruce Berkowitz would check if a small edge can widen further.

Gross profit growth of 804.39% while RVPH is zero. Bruce Berkowitz would see if minimal improvements could expand further.

Positive EBIT growth while RVPH is negative. John Neff might see a substantial edge in operational management.

Positive operating income growth while RVPH is negative. John Neff might view this as a competitive edge in operations.

Positive net income growth while RVPH is negative. John Neff might see a big relative performance advantage.

Positive EPS growth while RVPH is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.

Positive diluted EPS growth while RVPH is negative. John Neff might view this as a strong relative advantage in controlling dilution.

Share reduction more than 1.5x RVPH's 43.43%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.

Diluted share reduction more than 1.5x RVPH's 43.43%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.

Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.

Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.

Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.

Positive OCF/share growth while RVPH is negative. John Neff might see a comparative advantage in operational cash viability.

Positive 3Y OCF/share CAGR while RVPH is negative. John Neff might see a big short-term edge in operational efficiency.

Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.

Positive 5Y CAGR while RVPH is negative. John Neff might view this as a strong mid-term relative advantage.

Positive short-term CAGR while RVPH is negative. John Neff would see a clear advantage in near-term profit trajectory.

10Y equity/share CAGR above 1.5x RVPH's 452.59%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.

Positive short-term equity growth while RVPH is negative. John Neff sees a strong advantage in near-term net worth buildup.

No Data available this quarter, please select a different quarter.

No Data available this quarter, please select a different quarter.

Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.

Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.

Our R&D shrinks while RVPH invests at 118.95%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.

We cut SG&A while RVPH invests at 24.45%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.